A McGill-led systematic review of 38 clinical trials compares the weight-loss effects and safety profiles of current GLP-1 medications and emerging treatments.
On September 1, 2026, researchers published an updated systematic review evaluating current and emerging weight-loss medications. The study was led by researchers at McGill University and the Lady Davis Institute for Medical Research. They examined 38 randomized controlled trials involving 25,816 adults with overweight or obesity who did not have diabetes. To ensure a robust analysis, the researchers searched MEDLINE, Embase and the Cochrane Central Register of Controlled Trials for studies published through March 25, 2026.
The updated review added 14 newly identified trials and approximately 11,000 participants to an earlier analysis conducted by the research team. The included trials had to last at least 16 weeks to meet the study criteria. The review was registered with PROSPERO under registration number CRD42024505558 and reported no primary funding source. This level of rigor helps clinicians and patients make better-informed decisions about metabolic health.
When the new class of weight-loss medications started dominating the news, the media reaction was entirely polarized. It was framed as either a magic fix or a moral failing. Our team saw a huge need for calm, objective reporting. We decided to cover these medications exactly like any other tool by analyzing the clinical data, the benefits and the limitations without any judgment.
In our experience, the response from our readers showed just how starved people were for facts over feelings. This McGill review provides exactly the kind of objective data we rely on at WeightRestart. It sets realistic expectations regarding next-generation treatments while reinforcing the ongoing necessity of supportive lifestyle habits.
The review reflects a significant shift in the biological mechanisms used for medical weight management. Early treatments focused on a single metabolic pathway by mimicking a hormone called GLP-1. Medications like liraglutide and semaglutide work primarily through this established single mechanism. They interact with receptors to influence metabolic function, digestion and appetite.
The treatment landscape is now moving toward medicines that activate multiple metabolic pathways simultaneously. The researchers evaluated emerging multiagonists that combine GLP-1 action with other targets like GIP or glucagon. These multi-target compounds include tirzepatide, amycretin and retatrutide. The authors noted that head-to-head findings suggest treatment selection will increasingly involve comparisons among different mechanisms and delivery methods.
The delivery methods themselves are also expanding beyond traditional injectable therapies. The review evaluated oral semaglutide and an investigational oral agent called orforglipron alongside the injectable options. Providing a variety of administration methods allows patients to choose a format that aligns with their daily habits. Because appetite regulation relies heavily on biological signaling rather than simple willpower, having multiple treatment pathways improves the likelihood of finding a sustainable medical match.
This expansion underscores why understanding prescription weight-management medications requires looking beyond single-drug solutions.
Mainstream coverage often presents clinical percentages as promised outcomes for anyone seeking weight reduction. The reality is that the review reports average placebo-subtracted effects across distinct trial populations. Individual responses can differ widely because of baseline weight, dose, adherence, treatment duration and tolerability. Furthermore, the amount of lifestyle support provided in a trial directly influences the final outcome.
The hype also blurs the line between widely approved therapies and experimental drugs. The McGill announcement identifies amycretin and retatrutide strictly as emerging multiagonists that are still being tested. Their trial results should not be interpreted as evidence that they are approved or routinely available. They remain pipeline compounds that require further evaluation before entering general practice.
Tolerability is another area where the clinical reality challenges the enthusiastic media narrative. Gastrointestinal adverse events were common in the review. They affected 76.0% of participants receiving GLP-1-based therapy compared with 40.1% of those receiving a placebo. While the review reported no new safety signals, side effects matter significantly for long-term adherence.
Serious adverse events occurred in 6.5% of treated participants and 5.2% of placebo participants. Discontinuation because of adverse events occurred in 10.7% of the treatment group and 3.4% of the placebo group. Deaths were reported in 0.1% and 0.0% respectively. However, safety outcomes were reported inconsistently across studies, and heterogeneity between trials prevented the researchers from quantitatively synthesizing all results.
Finally, the precise percentages from different trials are not always directly comparable. The drugs were evaluated in different study populations with varying protocols. A 23.9% result for amycretin should therefore not be treated as proof that it will outperform other medications in real-world settings. Additionally, the review focused exclusively on adults without diabetes, meaning the outcomes should not automatically be generalized to excluded populations.
The results were reported as weight loss beyond that achieved by a placebo group. This placebo-subtracted metric is crucial because placebo groups may also lose weight through trial participation, counseling or behavioral support. The researchers documented distinct differences among both established and emerging treatments.
Among commercially available treatments, the trials demonstrated a broad range of efficacy. Placebo-subtracted weight loss reached approximately 5.8% with liraglutide. Injectable semaglutide achieved 14.8%, while oral semaglutide produced a 14.3% reduction. Tirzepatide produced the largest reductions among the available options, reaching 19.0% in the included trials.
The McGill summary contextualized these numbers by identifying semaglutide as the active ingredient in Wegovy and Ozempic. The summary notes that semaglutide produced results approaching 15% in several studies. Meanwhile, tirzepatide, the active ingredient in Mounjaro, produced losses of up to 19%.
The review also found evidence of differences in direct comparisons. Semaglutide and JNJ-64565111 produced greater weight loss than liraglutide. Additionally, tirzepatide and CagriSema produced greater weight loss than semaglutide in the relevant comparisons.
The emerging multi-target drugs produced numerically larger reductions in the trials where they were evaluated. Amycretin was associated with a 23.9% placebo-subtracted weight loss. Retatrutide was associated with a 22.1% reduction. The McGill article described these figures more broadly as nearly 24% for amycretin and up to 22% for retatrutide.
Another drug currently in development, orforglipron, was also included in the systematic review. This investigational oral agent achieved a 12.4% placebo-subtracted weight reduction. As with amycretin and retatrutide, these figures represent trial averages rather than established clinical expectations.
Large initial losses do not automatically establish long-term maintenance after a patient stops taking the medication. A look at the STEP 1 extension trial provides essential context for the maintenance challenge for weight-loss medications. In the STEP 1 extension, people who stopped semaglutide regained 11.6 percentage points of body weight during the following year. This left a net reduction of 5.6% from baseline at week 120.
A later report summarizing treatment-continuity evidence offers further insight into this dynamic. That report describes this outcome as approximately two-thirds of the original weight loss being regained after semaglutide withdrawal. This highlights the importance of discussing long-term weight regain after stopping GLP-1 medications before beginning a treatment plan.
Additionally, body composition remains a complex variable that scale weight alone cannot capture. A separate 2026 review evaluated the evidence concerning changes in muscle quantity and quality during treatment. That review found that current comparative research does not yet establish that GLP-1-based treatment preferentially preserves skeletal muscle.
The researchers in the body composition review documented substantial heterogeneity across the literature. They noted wide confidence intervals and low to very low certainty for conclusions about fat loss and muscle preservation. For midlife adults, monitoring physical function and preserving strength is just as important as tracking scale weight.
As the medical community expands its reliance on multi-target therapies, future research must clarify the best protocols for long-term maintenance. The evidence shows that stopping treatment often leads to substantial regain, meaning the industry needs rigorous studies on stepping down dosages or transitioning to behavioral support. We also need higher-quality comparative data to definitively understand how these medications impact skeletal muscle mass over time. Until those gaps are filled, these medications should be viewed as powerful tools that still require foundational habits in nutrition, movement and recovery.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
